189 related articles for article (PubMed ID: 27672107)
1. Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers.
Fumagalli D; Wilson TR; Salgado R; Lu X; Yu J; O'Brien C; Walter K; Huw LY; Criscitiello C; Laios I; Jose V; Brown DN; Rothé F; Maetens M; Zardavas D; Savas P; Larsimont D; Piccart-Gebhart MJ; Michiels S; Lackner MR; Sotiriou C; Loi S
Ann Oncol; 2016 Oct; 27(10):1860-6. PubMed ID: 27672107
[TBL] [Abstract][Full Text] [Related]
2. Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.
Chung JH; Pavlick D; Hartmaier R; Schrock AB; Young L; Forcier B; Ye P; Levin MK; Goldberg M; Burris H; Gay LM; Hoffman AD; Stephens PJ; Frampton GM; Lipson DM; Nguyen DM; Ganesan S; Park BH; Vahdat LT; Leyland-Jones B; Mughal TI; Pusztai L; O'Shaughnessy J; Miller VA; Ross JS; Ali SM
Ann Oncol; 2017 Nov; 28(11):2866-2873. PubMed ID: 28945887
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer.
Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Murakami K; Iwase H
Mol Cancer; 2018 Feb; 17(1):67. PubMed ID: 29482551
[TBL] [Abstract][Full Text] [Related]
4. Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer.
Basudan A; Priedigkeit N; Hartmaier RJ; Sokol ES; Bahreini A; Watters RJ; Boisen MM; Bhargava R; Weiss KR; Karsten MM; Denkert C; Blohmer JU; Leone JP; Hamilton RL; Brufsky AM; Elishaev E; Lucas PC; Lee AV; Oesterreich S
Mol Cancer Res; 2019 Feb; 17(2):457-468. PubMed ID: 30355675
[TBL] [Abstract][Full Text] [Related]
5. Liver tropism of ER mutant breast cancer is characterized by unique molecular changes and immune infiltration.
Wu Y; Li Z; Lee AV; Oesterreich S; Luo B
Breast Cancer Res Treat; 2024 Jun; 205(2):371-386. PubMed ID: 38427312
[TBL] [Abstract][Full Text] [Related]
6. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
7. ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).
Ferrando L; Vingiani A; Garuti A; Vernieri C; Belfiore A; Agnelli L; Dagrada G; Ivanoiu D; Bonizzi G; Munzone E; Lippolis L; Dameri M; Ravera F; Colleoni M; Viale G; Magnani L; Ballestrero A; Zoppoli G; Pruneri G
PLoS Genet; 2023 Jan; 19(1):e1010563. PubMed ID: 36595552
[TBL] [Abstract][Full Text] [Related]
8. Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer.
Akcakanat A; Zheng X; Cruz Pico CX; Kim TB; Chen K; Korkut A; Sahin A; Holla V; Tarco E; Singh G; Damodaran S; Mills GB; Gonzalez-Angulo AM; Meric-Bernstam F
Clin Cancer Res; 2021 Jun; 27(11):3243-3252. PubMed ID: 33782032
[TBL] [Abstract][Full Text] [Related]
9. Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies.
Carene D; Tran-Dien A; Lemonnier J; Dalenc F; Levy C; Pierga JY; Jacot W; Canon JL; Richon C; Lacroix L; Caux C; André F; Michiels S
Breast Cancer Res Treat; 2020 Jan; 179(2):387-401. PubMed ID: 31620934
[TBL] [Abstract][Full Text] [Related]
10. Preexisting Somatic Mutations of Estrogen Receptor Alpha (
Dahlgren M; George AM; Brueffer C; Gladchuk S; Chen Y; Vallon-Christersson J; Hegardt C; Häkkinen J; Rydén L; Malmberg M; Larsson C; Gruvberger-Saal SK; Ehinger A; Loman N; Borg Å; Saal LH
JNCI Cancer Spectr; 2021 Apr; 5(2):. PubMed ID: 33937624
[TBL] [Abstract][Full Text] [Related]
11. Concordance of genomic alterations between primary and recurrent breast cancer.
Meric-Bernstam F; Frampton GM; Ferrer-Lozano J; Yelensky R; Pérez-Fidalgo JA; Wang Y; Palmer GA; Ross JS; Miller VA; Su X; Eroles P; Barrera JA; Burgues O; Lluch AM; Zheng X; Sahin A; Stephens PJ; Mills GB; Cronin MT; Gonzalez-Angulo AM
Mol Cancer Ther; 2014 May; 13(5):1382-9. PubMed ID: 24608573
[TBL] [Abstract][Full Text] [Related]
12. Comparative genomic analysis of primary tumors and metastases in breast cancer.
Bertucci F; Finetti P; Guille A; Adélaïde J; Garnier S; Carbuccia N; Monneur A; Charafe-Jauffret E; Goncalves A; Viens P; Birnbaum D; Chaffanet M
Oncotarget; 2016 May; 7(19):27208-19. PubMed ID: 27028851
[TBL] [Abstract][Full Text] [Related]
13. Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases.
Schrijver WAME; Selenica P; Lee JY; Ng CKY; Burke KA; Piscuoglio S; Berman SH; Reis-Filho JS; Weigelt B; van Diest PJ; Moelans CB
Cancer Res; 2018 Jun; 78(12):3112-3121. PubMed ID: 29615433
[TBL] [Abstract][Full Text] [Related]
14. ESR1 and PIK3CA mutational status in serum and plasma from metastatic breast cancer patients: A comparative study.
Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Iwase H
Cancer Biomark; 2018; 22(2):345-350. PubMed ID: 29689710
[TBL] [Abstract][Full Text] [Related]
15. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
Zundelevich A; Dadiani M; Kahana-Edwin S; Itay A; Sella T; Gadot M; Cesarkas K; Farage-Barhom S; Saar EG; Eyal E; Kol N; Pavlovski A; Balint-Lahat N; Dick-Necula D; Barshack I; Kaufman B; Gal-Yam EN
Breast Cancer Res; 2020 Feb; 22(1):16. PubMed ID: 32014063
[TBL] [Abstract][Full Text] [Related]
16. Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.
Lefebvre C; Bachelot T; Filleron T; Pedrero M; Campone M; Soria JC; Massard C; Lévy C; Arnedos M; Lacroix-Triki M; Garrabey J; Boursin Y; Deloger M; Fu Y; Commo F; Scott V; Lacroix L; Dieci MV; Kamal M; Diéras V; Gonçalves A; Ferrerro JM; Romieu G; Vanlemmens L; Mouret Reynier MA; Théry JC; Le Du F; Guiu S; Dalenc F; Clapisson G; Bonnefoi H; Jimenez M; Le Tourneau C; André F
PLoS Med; 2016 Dec; 13(12):e1002201. PubMed ID: 28027327
[TBL] [Abstract][Full Text] [Related]
17. Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences.
Priedigkeit N; Ding K; Horne W; Kolls JK; Du T; Lucas PC; Blohmer JU; Denkert C; Machleidt A; Ingold-Heppner B; Oesterreich S; Lee AV
Breast Cancer Res; 2021 Jan; 23(1):1. PubMed ID: 33407744
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
[TBL] [Abstract][Full Text] [Related]
19. Genetic alterations and their association with clinicopathologic characteristics in advanced breast carcinomas: focusing on clinically actionable genetic alterations.
Freitag CE; Mei P; Wei L; Parwani AV; Li Z
Hum Pathol; 2020 Aug; 102():94-103. PubMed ID: 32445652
[TBL] [Abstract][Full Text] [Related]
20. Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine.
Levin MK; Wang K; Yelensky R; Cao Y; Ramos C; Hoke N; Pippen J; Blum JL; Brooks B; Palmer G; Palma N; Balasubramanian S; Ross JS; O'Shaughnessy J
Cancer Med; 2015 Aug; 4(8):1289-93. PubMed ID: 25871911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]